Combined inhibition of ACLY and CDK4/6 reduces cancer cell growth and invasion

The use of small molecule kinase inhibitors, which target specific enzymes that are overactive in cancer cells, has revolutionized cancer patient treatment. To treat some types of breast cancer, CDK4/6 inhibitors, such as palbociclib, have been developed that target the phosphorylation of the retino...

Descripción completa

Detalles Bibliográficos
Autores principales: Velez, Brian Christopher, Petrella, Christopher Paul, DiSalvo, Kathleen Helen, Cheng, Keyi, Kravtsov, Rebecca, Krasniqi, Dorina, Krucher, Nancy Ann
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9827262/
https://www.ncbi.nlm.nih.gov/pubmed/36562384
http://dx.doi.org/10.3892/or.2022.8469

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9827262/
https://www.ncbi.nlm.nih.gov/pubmed/36562384
http://dx.doi.org/10.3892/or.2022.8469

Ejemplares similares